EMA Authorised: Emadine (emedastine difumarate) — Immedica Pharma AB

View source ↗

Summary

The European Medicines Agency authorised Emadine (emedastine difumarate) for allergic conjunctivitis, with Immedica Pharma AB as the marketing authorization hol…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Conjunctivitis

Drugs mentioned

• Emadine (emedastine difumarate)

Snippet

Status: Authorised. Therapeutic area: Conjunctivitis, Allergic. MAH: Immedica Pharma AB. Decision date: 20/02/2025